USPTO serial 79224525
AYOXXA
Reviewed by CopyMark Law Group
Reg. 5705785Status 709
- Filing date
- Status date
- Registration date
- Mar 26, 2019
- Examiner
- BERLIN, JUSTIN E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AYOXXA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joyce von Natzmer
Joyce von Natzmer Agris & von Natzmer LLP43 West 43rd Street, Suite 104New York, NY 10036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical purposes; chemical and biochemical preparations for veterinary purposes, namely, for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; chemical and biochemical reagents for veterinary purposes; chemical and biochemical preparations for pharmaceutical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical or veterinary pharmaceutical purposes; biological agents for laboratory analyses for medical purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for medical purposes; biological agents for laboratory analyses for veterinary purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for veterinary purposes; chemical and biochemical preparations and reagents for medical purposes, namely, for use in DNA analyses; chemical and biochemical preparations for blood tests for medical purposes; chemical and biochemical reagents for blood tests for medical purposes; chemical and biochemical preparations for blood tests for veterinary purposes; chemical and biochemical reagents for blood tests for veterinary purposes; peptides, proteins, nucleic acids and other biomolecules, or complexes of these molecules, for medical purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for the treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases, protein arrays for medical diagnosis purposes, nucleic acid sequences for medical diagnosis purposes; proteins, nucleic acids and other biomolecules, or complexes of these molecules, for veterinary purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations in animals, protein arrays for veterinary diagnosis purposes, nucleic acid sequences for veterinary diagnosis purposes; chemical and biochemical preparations and reagents for labelling of molecules for medical detection and monitoring purposes; chemical and biochemical preparations and reagents for labelling of molecules for veterinary detection and monitoring purposes | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 10, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 10, 2025 | C71T | CANCELLED SECTION 71 | — |
| Mar 26, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 1, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 16, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 25, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 25, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 26, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 19, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 14, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 22, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 21, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 21, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 21, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2018 | RFNP | REFUSAL PROCESSED BY IB | — |
| Mar 22, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 22, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 22, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 21, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 16, 2018 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Feb 7, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 6, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 16, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 16, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 10, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 4, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |